ONCE Spark Therapeutics, Inc.

57.13
-0.16  -0.29%
Previous Close 57.29
Open 57.19
Price To book 4.90
Market Cap 1.76B
Shares 30,773,000
Volume 298,064
Short Ratio 8.56
Av. Daily Volume 461,298

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 4Q 2016 with initial data due mid 2017.
SPK-8011
Hemophilia A
Phase 1/2 updated data at ASH 2016. Further update due 1H 2017.
SPK-9001
Hemophilia B
Phase 1/2 dosing commenced 1Q 2015. Initial data due early 2017.
SPK-7001 (SPK-CHM)
Choroideremia
BLA filing due early 2017.
SPK-RPE65
Inherited retinal dystrophies

Latest News

  1. Spark Therapeutics Announces U.S. Orphan Drug Designation Amendment and Study Updates for Lead Investigational Gene Therapy
  2. Spark Gets A Check From Pfizer And A Downgrade From Vetr
  3. Spark Therapeutics, Inc. – Value Analysis (NASDAQ:ONCE) : January 5, 2017
  4. Company News for January 05, 2017
  5. Spark Therapeutics Gets $15M Milestone Payment from Pfizer
  6. Spark reels in second $15M payment from Pfizer
  7. Spark Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ONCE-US : January 4, 2017
  8. Spark Therapeutics Announces $15 Million Milestone Payment from Pfizer for Progress in Hemophilia B Gene Therapy Program
  9. Spark Therapeutics to Participate in J.P. Morgan Healthcare Conference
  10. Massive Bill Ackman Trade Highlights Insider Selling: Valeant Pharmaceuticals, Starbucks, Schlumberger, Validus and More
  11. Is MRC Global Inc (MRC) A Good Stock To Buy?
  12. SPARK THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
  13. Spark Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ONCE-US : December 8, 2016
  14. Hedge Funds Aren’t Crazy About Spark Therapeutics Inc (ONCE) Anymore
  15. Rivals Kite Pharma, Juno Therapeutics Tank On Cancer Data; Spark Flies
  16. SPARK THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  17. Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting
  18. Here’s Why We Think There’s Opportunity In Uniqure NV (QURE)
  19. Spark lights up licensing deal valued at up to $460M
  20. Spark Therapeutics Adds Chief Operating Officer to Management Team